World Orphan Drug Congress 2018 Covance Whitepaper
community download

World Orphan Drug Congress 2018 Covance Whitepaper

information we require

please check before submitting



Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

 

Connecting With Rare Disease Patient Communities: Patient Advocates.

Best Practices for Contract Research Organizations and Sponsors

 

The biopharmaceutical industry is increasingly incorporating the voice of the patient in the drug development process, but how effective are these interactions from the perspective of rare disease patients? To explore this question, Covance recently spoke with four leaders who have established their own patient advocacy groups and foundations. We wanted to hear about their unique experiences – both as people living with rare diseases and trailblazers for patient advocacy – to gather practical recommendations for the drug development industry.

 

This article focuses on how to strengthen the connections between rare disease communities and a network of stakeholders, specifically examining how to best create mutually beneficial relationships of members of the patient community with contract research organizations (CROs) and Sponsors.

 

To learn more about Covance , visit their website.